Hub Workflow Orchestration: How Pharma Patient Hubs Run on AI [2026]
Hub Workflow Orchestration: How Pharma Patient Hubs Run on AI [2026]
A pharma patient hub in 2026 runs eight to twelve named workflows in parallel. Intake. Benefit verification. Prior authorization. Copay and foundation enrollment. Specialty pharmacy routing. REMS attestation. Adherence outreach. Missing-information loops. Appeals. Reauthorization. Reporting back to the manufacturer. Until recently, each of those workflows lived in a different system run by a different team, and the work of connecting them was a clipboard.
That clipboard is what hub workflow orchestration replaces. Orchestration is the layer that sequences the hub's discrete workflows into one accountable pipeline where every patient case has a state, every state has a next action, and every action has an owner. The shift in 2026 is that the owner is increasingly an AI worker, not because AI is cheaper but because the workflow can no longer be run end-to-end by humans at the volume specialty pharma now ships.
The stakes are concrete. Only 22% of prescribers say specialty therapy initiates in two weeks or less, despite 82% believing it should (Surescripts Specialty Medications Data Brief, 2022). Seventy-eight percent of physicians report that prior authorization causes patients to abandon a recommended course of treatment (AMA 2024 Prior Authorization Survey). The global pharma hub and patient access support service market is projected to reach $7.63 billion by 2033 from $3.24 billion in 2024, a 10% CAGR (Grand View Research). The orchestration layer is where the budget and the patient outcome meet.
Most coverage of patient hubs is either a vendor matrix or a thought-leadership piece on AI. This guide is the operator-side answer: what each hub workflow actually looks like, where AI works in 2026, where it does not, and what an end-to-end orchestrated hub looks like in practice.
At Neon Health, we build the AI workforce that runs these workflows in production. Voice agents that call payers, portal automation that navigates fax queues and payer portals, rules engines that decide what gets routed to a human. The piece below reflects what we see across hub deployments.
What Is Hub Workflow Orchestration?
Hub workflow orchestration is the layer that sequences a patient hub's discrete workflows into one accountable pipeline with state tracking, decisioning logic, and exception routing.
Automation runs one task. Orchestration sequences many across systems, channels, and exception types. A benefit verification tool that calls a payer is automation. A platform that intakes a referral, validates demographics, calls the payer, parses the response, decides whether to submit a prior authorization, and routes the case to a human only when it cannot continue, is orchestration.
The distinction is not academic. A hub running point tools handles each workflow well in isolation but loses visibility across handoffs. An orchestrated hub treats the entire case as the unit of work. State, owner, and next action are tracked for every patient at every moment.
Dimension | Automation | Orchestration |
|---|---|---|
Scope | One task | Many workflows across the patient journey |
State | Owned by each tool | One state machine spans the case |
Channels | Single (portal, voice, or fax) | Composed across portal, voice, fax, API, EHR |
Owner | The tool that ran the task | The case (human or AI handles current state) |
Exception handling | Errors return to a queue | Exceptions routed by rules and history |
Why this matters now: specialty drugs dominate new approvals. In 2023, more than half of the 55 novel drugs approved by the FDA were for rare diseases, and the trend has continued (Grand View Research). Each launch adds eight to twelve workflows on top of an existing pipeline. Hiring cannot scale linearly with launch volume. Orchestration is what makes the work scale.
The Eight Workflows Every Hub Runs
A modern hub runs eight discrete workflow domains. Each one breaks in predictable ways, each one has well-defined AI primitives in 2026, and each one has a metric the hub leader watches every week.
Intake and Patient Onboarding
Intake is where the case starts. A referral arrives by fax (still roughly half of inbound intake at most hubs, per industry analysis), by portal submission, by EHR integration, or by API. The hub has to pull a complete patient record, verify the prescriber, capture HIPAA and TCPA consent, and advance to benefit verification.
Where it breaks: missing demographics, illegible faxes, prescriber identifiers that do not match NPI directories, consent forms returned without signatures. A typical hub sees 20 to 40% of inbound referrals require at least one round of clarification before BV can start.
Where AI works in 2026: optical character recognition and structured extraction on fax images, language model parsing of unstructured clinical notes, completeness checks that block advancement until a case is workable. Outbound voice agents that call the prescriber office to fill gaps.
Metric to watch: time from referral receipt to BV-ready case. A high-performing hub targets under four hours.
Benefit Verification
Benefit verification confirms the patient's coverage for a specific specialty drug. EDI 270/271 transactions return basic eligibility, but they miss specialty-specific rules: step therapy sequences, J-code formulary status, site-of-care restrictions, and prior authorization triggers.
Where it breaks: payer portals change without notice. Phone IVR menus loop. Plan-specific eligibility data is stale or contradictory across sources. Specialty drugs often require coordination of medical and pharmacy benefit coverage in the same case.
Where AI works in 2026: voice agents that call payer help lines and navigate IVR trees. Portal automation that logs into UnitedHealthcare, Aetna, Cigna, and Blue Cross subsidiaries and extracts the benefit summary. Language model extraction of benefit response documents into structured fields the rest of the workflow can consume.
Metric to watch: BV completion rate within 24 hours of intake.
Prior Authorization
Prior authorization is the most consequential workflow in the hub. The AMA's 2024 nationwide survey of 1,000 practicing physicians found that 78% report PA leads to patient treatment abandonment, 94% report PA delays patient access to care, and 19% report PA-driven serious adverse events that led to hospitalization (AMA 2024 Prior Authorization Survey). On average, a physician's practice completes 43 PAs per physician per week and spends 12 hours of staff time per week on the workflow.
Where it breaks: payer-specific clinical criteria, missing chart pulls, peer-to-peer requirements, appeals loops that restart the clock.
Where AI works in 2026: medical policy matching against the patient chart, pre-filled questionnaires extracted from clinical documentation, electronic PA submission through CoverMyMeds and similar networks, appeal letter drafting against denial reasons.
A compliance note worth flagging. CMS-0057-F's 72-hour and 7-day PA decision timeframes and FHIR API requirements explicitly exclude drug prior authorizations. The rule applies to medical items and services. Drug PA remains governed by state PA reform laws (which vary widely) and payer contracts. Any hub operating across multiple drugs and multiple states must build state-by-state PA compliance.
Metric to watch: PA submission turnaround and approval rate by payer.
Copay and Financial Assistance Enrollment
A specialty drug at a $500 monthly copay produces a different abandonment curve than the same drug at a $50 copay. Specialty drug abandonment rates climb from 1.3-10% at low cost sharing to 32-75% when patient cost sharing exceeds $100 (peer-reviewed analysis cited across specialty pharmacy literature). The hub's job is to find a copay card, foundation grant, or patient assistance program that takes the out-of-pocket cost out of the abandonment zone.
Where it breaks: foundation funding windows open and close; eligibility documentation expires; anti-kickback safeguards constrain how routing decisions get made; independent 501(c)(3) foundations require strict separation from manufacturer influence.
Where AI works in 2026: foundation match against diagnosis, household income, and insurance type. Document collection workflows that text or email the patient for proof of income. Recertification reminders before grants expire. Audit logging that demonstrates AKS-compliant routing.
Metric to watch: percentage of cases with cost sharing reduced to under $50 within seven days of BV.
Fulfillment and Specialty Pharmacy Routing
Once coverage and affordability are resolved, the hub routes the patient to a specialty pharmacy or infusion site. Payer-mandated limited distribution networks complicate this: the patient's preferred pharmacy may not be the one the payer requires.
Where it breaks: limited distribution network mismatches, cold chain coordination for biologics, site-of-care decisions when both home infusion and infusion center are viable.
Where AI works in 2026: routing logic that resolves network constraints against patient geography. Shipment status tracking. Refill orchestration that anticipates the next ship date and starts the workflow early enough to prevent gaps.
Metric to watch: first-fill ship date vs. PA approval date.
REMS and Regulatory Attestation
The FDA maintains active Risk Evaluation and Mitigation Strategies (REMS) programs for medications where serious safety risks require additional controls beyond standard labeling (FDA REMS). REMS applies to drugs, not medical services. The compliance burden falls on hubs, specialty pharmacies, and prescribers who must verify enrollment, complete training, and document patient-level attestations.
Where it breaks: prescriber enrollment lapses, pharmacy certification gaps, missed lab attestations, patient counseling documentation that fails audit.
Where AI works in 2026: workflow gating that blocks dispense events without a current REMS attestation. Reminder workflows for prescriber re-enrollment. Audit log capture for every REMS-relevant action.
Metric to watch: zero REMS-related ship blocks at audit, zero dispense events without attestation.
Adherence and Care Coordination
Once the patient is on therapy, the hub's job is keeping them on therapy. Refill timing, missed-dose intervention, side effect triage, lab and follow-up coordination.
Where it breaks: patient phone numbers go stale; refills lapse without notice; side effects cause patients to stop without telling anyone.
Where AI works in 2026: outbound check-in calls with structured questions and natural conversational handling. Persistence prediction models that flag at-risk patients to a human nurse case manager. Side effect triage that follows clinical protocols and escalates when patient-reported symptoms cross a defined threshold.
Metric to watch: persistence at 90 and 180 days.
Missing Information Resolution and Exception Loops
The eighth workflow is the one most hub leaders underestimate. The majority of cases at any given moment are not progressing because something is missing from the prescriber, the payer, or the patient. Phone numbers that need a callback. Lab values not yet returned. PA denial reasons that need an appeal.
Where AI works in 2026: outbound calls and faxes back to prescriber offices. Pattern recognition on which information is most often missing per payer, allowing the hub to ask for it upfront on the next case. Automated re-requests against a clock.
Metric to watch: number of cases in "awaiting information" state at the start and end of each day.
What an Orchestrated Hub Actually Looks Like
The eight workflows above can be run in three meaningfully different ways. The architecture choice determines whether the hub scales with launches or breaks under them.
Architecture | How it runs | Where it breaks |
|---|---|---|
Sequential manual | Call center, spreadsheets, fax queues, email handoffs | Errors compound across handoffs; no visibility across cases; cannot absorb launch volume |
Point-tool stack | ePA tool, eBV tool, CRM, separate adherence platform, each owning state | Each tool owns its own data; manual reconciliation; gaps between tools; no single view of the case |
AI workforce orchestration | One state machine, AI agents own discrete workflows, humans handle exceptions | Requires AI maturity; harder to procure; tied to vendor's roadmap if not consultative |
The orchestrated architecture, the one Neon Health builds for, treats the case as the unit of work. Every case has one of roughly 15 named states, every transition is logged, every action attaches to either an AI agent or a human owner. The decisioning layer is where rules, AI judgment, and human-in-the-loop intersect. Routine BV calls go to the voice agent. A case where the payer's portal has been redesigned overnight goes to a human, while the system learns the new portal flow for next time.
This is not theoretical. The CAQH 2025 Index documents that the U.S. healthcare system avoided $258 billion in administrative costs in 2024 through electronic transactions and improved data exchange, with a remaining $21 billion opportunity in administrative workflows that are still manual or only partially automated (CAQH 2025 Index). More than 50% of health plans and 25% of provider organizations now use AI tools in administrative workflows. Pharma hubs sit squarely in that automation opportunity.
The ROI math at the case level is directional, not precise. A small reduction in time-to-BV compresses time-to-therapy. Time-to-therapy correlates with abandonment risk. Reduced abandonment means more patients on therapy, more revenue at the manufacturer level, and lower cost-per-patient at the hub level. Pinning a precise dollar figure to a single case requires assumptions about drug price, payer mix, and abandonment curve that vary by program. What does not vary is the direction.
The 2026 Vendor Landscape
Three categories of vendor compete for orchestration spend in 2026. None of them owns the term "hub workflow orchestration" yet, which is part of why the term is worth defining clearly.
Full-service hub providers run end-to-end execution. ConnectiveRx, Lash Group, AssistRx, CareMetx, Eversana, and McKesson RxO each operate large patient access programs with their own technology platforms and human teams. Orchestration in these models is a workflow management feature inside a service offering, not the product itself. Industry consolidation has shaped what these stacks look like: Eversana acquired Dohmen Life Sciences Services, CareMetx acquired Biosolutia and Virmedica, ConnectiveRx acquired Macaluso Group. Each acquisition added a workflow capability that the parent then integrated. The result is broad coverage with depth that varies by acquired component.
AI-native automation layers treat orchestration as the core product. Mandolin raised $40 million in June 2025 and has deployed across more than 700 clinical locations, with AI agents that handle intake, benefit verification, out-of-pocket estimation, prior authorization, claims, and appeals (BusinessWire, June 2025). Infinitus partnered with IBM Consulting in 2025 to bring agentic AI into specialty pharmacy workflows targeted at PA cycle time and BV (MobiHealthNews). Neon Health composes voice agents, portal automation, and rules engines into bespoke orchestration for each customer, with HIPAA, HITRUST, and SOC 2 as the floor.
Point tools solve one slice deeply. CoverMyMeds for ePA. Surescripts for eBV and electronic prescription routing. Waystar for claims and revenue cycle. Salesforce Health Cloud for case management. None of these is an orchestrator by itself, but each plays a role inside one. A full-service hub or AI-native layer typically integrates several point tools and adds the orchestration layer on top.
The investment signal in this market is clear. The Grand View Research projection of $7.63 billion by 2033 includes AI integration as a primary growth driver. The report cites Wellgistics Health's August 2025 launch of HubRx AI, an AI platform automating eligibility checks, claims management, and reimbursement support, as one example of what AI orchestration looks like in practice (Grand View Research).
For a head-to-head comparison of patient hub platforms with named pricing tiers and feature breakdowns, see our patient hub platforms guide. The piece here is the workflow-orchestration layer that sits above any of those platforms.
Compliance and Regulatory Architecture
A modern hub crosses a wide compliance surface every day. The orchestration layer is what makes the surface auditable.
Regulation | Scope | Where it touches the workflow |
|---|---|---|
HIPAA / HITECH | PHI handling | Every system, every BAA, encryption in transit and at rest |
HITRUST CSF | Information security framework | Independent certification of HIPAA-aligned controls |
SOC 2 | Trust services criteria | Independent audit of security, availability, confidentiality |
TCPA | Outbound calls and texts | Express written consent required before outbound contact |
AKS (Anti-Kickback Statute) | Foundation routing, PAP design | No prescriber-induced steering, independent foundation governance |
FDA REMS | Drug-level FDA mandates | Workflow gating on attestation; applies to drugs, not services |
Sunshine Act | Manufacturer payments | Limited reporting requirements, usually routed through foundations |
State PA reform laws | Prior authorization timelines | Vary by state; drug PA is state-governed, not CMS-0057-F-governed |
A few subtleties worth naming.
REMS applies to drugs, not medical services. The FDA maintains a current list of approved REMS programs on its REMS page (FDA REMS); only a small subset of medications require one, but for those that do, orchestration must hard-block dispense events when REMS attestation is missing or expired. Soft-block patterns lead to audit findings.
CMS-0057-F's PA reform requirements, including the 72-hour decision timeframe and FHIR API mandates, explicitly exclude drug prior authorizations. The rule applies to medical items and services. The follow-on CMS-0062-P proposed rule, released by CMS in 2026, would extend several of the same interoperability and PA requirements to drug PA, but it is a proposed rule and has not been finalized at the time of writing (CMS-0062-P). Today, drug PA timelines remain governed by state PA reform laws and payer-specific contracts. Hubs operating across multiple drugs and multiple states should track the CMS-0062-P finalization while building state-by-state compliance.
The audit-trail requirement runs through everything. AI orchestration must produce a per-case, per-action audit log: every outbound call, every payer portal action, every clinical attestation, every state transition. Procurement teams at pharma manufacturers will not approve a vendor whose audit log cannot answer the question "what did the AI agent do at 11:43 on Tuesday for patient X?"
Frequently Asked Questions
What is the difference between a patient hub and hub workflow orchestration?
The patient hub is the program: the team, technology, and services running patient access for a specialty drug. Hub workflow orchestration is the layer that sequences the hub's discrete workflows (intake, BV, PA, copay, fulfillment, REMS, adherence) into one accountable pipeline with state tracking and decisioning logic. A hub can exist without orchestration; it just runs slower and with more handoffs.
How is AI changing hub services in 2026?
AI is replacing manual portal navigation, payer phone calls, and document extraction with AI agents that run the same workflows around the clock. The 2025 CAQH Index reports that more than 50% of health plans and 25% of providers now use AI tools in administrative workflows (CAQH 2025 Index). The shift specific to hub operations is from single-task automation to end-to-end orchestration.
Does hub workflow orchestration require integrations with payer systems?
Not always. A modern AI workforce can operate the same channels a human team uses: payer portals, IVR phone trees, and fax. Integration accelerates execution where APIs exist, but the absence of an API is no longer a blocker for orchestration. This matters because most payers do not expose APIs for specialty drug coverage details.
What does HIPAA and HITRUST compliance mean for an AI hub?
Every AI agent action must produce an audit log, all PHI must be encrypted in transit and at rest, and access must be role-gated. HITRUST and SOC 2 certifications attest that controls have been independently audited. Pharma manufacturers gate vendor decisions on these certifications. A hub orchestration platform without HIPAA, HITRUST, and SOC 2 will not survive procurement at most pharma buyers.
How is hub workflow orchestration different from a specialty pharmacy management platform?
A specialty pharmacy platform runs the pharmacy itself: dispense, fulfillment, refill management, clinical coordination. Hub orchestration runs the upstream and downstream workflows that determine whether a prescription ever reaches the pharmacy: intake, BV, PA, copay, adherence, and reauthorization. The two work together; neither replaces the other.
Do CMS-0057-F prior authorization rules apply to drug PAs?
No. CMS-0057-F's 72-hour and 7-day decision timeframes and FHIR API requirements explicitly exclude drug prior authorizations. The rule applies to medical items and services. The follow-on CMS-0062-P proposed rule released in 2026 would extend similar requirements to drugs, but it is not yet final. Until then, drug PA timelines remain governed by state PA reform laws and payer-specific contracts.
Key Takeaways
Hub workflow orchestration sequences eight discrete workflows (intake, BV, PA, copay, fulfillment, REMS, adherence, exception handling) into one accountable pipeline with state tracking and decisioning logic.
The global pharma hub and patient access support service market is projected to reach $7.63 billion by 2033, growing at 10% CAGR, with AI integration as a primary growth driver (Grand View Research).
Only 22% of prescribers say specialty therapy initiates within two weeks despite 82% believing it should, a gap that reflects unorchestrated workflow debt (Surescripts Specialty Medications Data Brief).
Seventy-eight percent of physicians report that prior authorization leads to patient treatment abandonment, and 94% report PA delays care (AMA 2024 Prior Authorization Survey).
The 2026 shift in hubs is from single-task automation to AI workforce orchestration, with $21 billion in remaining administrative automation opportunity across U.S. healthcare (CAQH 2025 Index).
REMS applies to drugs, not medical services, and CMS-0057-F PA reform timelines explicitly exclude drug PAs. The 2026 CMS-0062-P proposed rule would extend PA requirements to drugs but is not final. Drug-level compliance requires separate workflow architecture (FDA REMS, CMS-0062-P).
HIPAA, HITRUST, and SOC 2 are the procurement floor for any hub orchestration vendor. A complete, per-case audit log is the operational floor.
Closing
The hub of 2026 is not a call center with technology bolted on. It is an orchestrated AI workforce composed of voice agents, portal automation, and decisioning, with humans handling exceptions. The vendors who win this decade will be the ones who treat orchestration as the product, not as a feature inside a service offering.
At Neon Health, we build that workforce. Modular voice, portal, and rules-engine components composed for each customer's workflows. HIPAA, HITRUST, and SOC 2 as the floor. Consultative implementation because no two hubs look the same.
For a head-to-head comparison of patient hub platforms, see patient hub platforms compared. For the workflow-level view of how AI agents fit into healthcare operations more broadly, see AI agents in healthcare. To see how Neon orchestrates these workflows for your program, schedule a consultation.
Sources
Primary Sources
AMA. "Exhausted by prior auth, many patients abandon care: AMA survey." 2024. https://www.ama-assn.org/practice-management/prior-authorization/exhausted-prior-auth-many-patients-abandon-care-ama-survey
CAQH. "2025 CAQH Index: $258 billion avoided through automation, interoperability, and AI adoption." 2025. https://www.caqh.org/blog/2025-caqh-index-shows-u.s.-healthcare-avoided-258-billion-and-accelerated-automation-interoperability-and-ai-adoption
CMS. "2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P)." 2026. https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p
FDA. "Risk Evaluation and Mitigation Strategies (REMS)." Accessed May 2026. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
Grand View Research. "Pharma Hub And Patient Access Support Service Market Report, 2024-2033." 2025. https://www.grandviewresearch.com/industry-analysis/pharma-hub-patient-access-support-service-market-report
Surescripts. "Specialty Medications Data Brief." 2022. https://surescripts.com/lp/specialty-medications-data-brief-2022
Secondary Sources
BusinessWire. "Mandolin Raises $40M to Improve Access to Life-Saving Therapies for Diseases like Cancer and Alzheimer's Using AI Agents." June 2025. https://www.businesswire.com/news/home/20250625104094/en/Mandolin-Raises-$40M-to-Improve-Access-to-Life-Saving-Therapies-for-Diseases-like-Cancer-and-Alzheimers-Using-AI-Agents
MobiHealthNews. "Infinitus, IBM Consulting team up for agentic AI." 2025. https://www.mobihealthnews.com/news/infinitus-ibm-consulting-team-agentic-ai
Pharmacy Times. "Accelerate Time to Specialty Pharmacy Therapy with Digital Options." https://www.pharmacytimes.com/view/accelerate-time-to-specialty-pharmacy-therapy-with-digital-options
AJMC. "2024 CAQH Index Foresees Major Opportunity for Health Care Savings." 2024. https://www.ajmc.com/view/2024-caqh-index-foresees-major-opportunity-for-health-care-savings
ConnectiveRx, Mandolin. Self-reported data from company websites. Accessed May 2026.
A pharma patient hub in 2026 runs eight to twelve named workflows in parallel. Intake. Benefit verification. Prior authorization. Copay and foundation enrollment. Specialty pharmacy routing. REMS attestation. Adherence outreach. Missing-information loops. Appeals. Reauthorization. Reporting back to the manufacturer. Until recently, each of those workflows lived in a different system run by a different team, and the work of connecting them was a clipboard.
That clipboard is what hub workflow orchestration replaces. Orchestration is the layer that sequences the hub's discrete workflows into one accountable pipeline where every patient case has a state, every state has a next action, and every action has an owner. The shift in 2026 is that the owner is increasingly an AI worker, not because AI is cheaper but because the workflow can no longer be run end-to-end by humans at the volume specialty pharma now ships.
The stakes are concrete. Only 22% of prescribers say specialty therapy initiates in two weeks or less, despite 82% believing it should (Surescripts Specialty Medications Data Brief, 2022). Seventy-eight percent of physicians report that prior authorization causes patients to abandon a recommended course of treatment (AMA 2024 Prior Authorization Survey). The global pharma hub and patient access support service market is projected to reach $7.63 billion by 2033 from $3.24 billion in 2024, a 10% CAGR (Grand View Research). The orchestration layer is where the budget and the patient outcome meet.
Most coverage of patient hubs is either a vendor matrix or a thought-leadership piece on AI. This guide is the operator-side answer: what each hub workflow actually looks like, where AI works in 2026, where it does not, and what an end-to-end orchestrated hub looks like in practice.
At Neon Health, we build the AI workforce that runs these workflows in production. Voice agents that call payers, portal automation that navigates fax queues and payer portals, rules engines that decide what gets routed to a human. The piece below reflects what we see across hub deployments.
What Is Hub Workflow Orchestration?
Hub workflow orchestration is the layer that sequences a patient hub's discrete workflows into one accountable pipeline with state tracking, decisioning logic, and exception routing.
Automation runs one task. Orchestration sequences many across systems, channels, and exception types. A benefit verification tool that calls a payer is automation. A platform that intakes a referral, validates demographics, calls the payer, parses the response, decides whether to submit a prior authorization, and routes the case to a human only when it cannot continue, is orchestration.
The distinction is not academic. A hub running point tools handles each workflow well in isolation but loses visibility across handoffs. An orchestrated hub treats the entire case as the unit of work. State, owner, and next action are tracked for every patient at every moment.
Dimension | Automation | Orchestration |
|---|---|---|
Scope | One task | Many workflows across the patient journey |
State | Owned by each tool | One state machine spans the case |
Channels | Single (portal, voice, or fax) | Composed across portal, voice, fax, API, EHR |
Owner | The tool that ran the task | The case (human or AI handles current state) |
Exception handling | Errors return to a queue | Exceptions routed by rules and history |
Why this matters now: specialty drugs dominate new approvals. In 2023, more than half of the 55 novel drugs approved by the FDA were for rare diseases, and the trend has continued (Grand View Research). Each launch adds eight to twelve workflows on top of an existing pipeline. Hiring cannot scale linearly with launch volume. Orchestration is what makes the work scale.
The Eight Workflows Every Hub Runs
A modern hub runs eight discrete workflow domains. Each one breaks in predictable ways, each one has well-defined AI primitives in 2026, and each one has a metric the hub leader watches every week.
Intake and Patient Onboarding
Intake is where the case starts. A referral arrives by fax (still roughly half of inbound intake at most hubs, per industry analysis), by portal submission, by EHR integration, or by API. The hub has to pull a complete patient record, verify the prescriber, capture HIPAA and TCPA consent, and advance to benefit verification.
Where it breaks: missing demographics, illegible faxes, prescriber identifiers that do not match NPI directories, consent forms returned without signatures. A typical hub sees 20 to 40% of inbound referrals require at least one round of clarification before BV can start.
Where AI works in 2026: optical character recognition and structured extraction on fax images, language model parsing of unstructured clinical notes, completeness checks that block advancement until a case is workable. Outbound voice agents that call the prescriber office to fill gaps.
Metric to watch: time from referral receipt to BV-ready case. A high-performing hub targets under four hours.
Benefit Verification
Benefit verification confirms the patient's coverage for a specific specialty drug. EDI 270/271 transactions return basic eligibility, but they miss specialty-specific rules: step therapy sequences, J-code formulary status, site-of-care restrictions, and prior authorization triggers.
Where it breaks: payer portals change without notice. Phone IVR menus loop. Plan-specific eligibility data is stale or contradictory across sources. Specialty drugs often require coordination of medical and pharmacy benefit coverage in the same case.
Where AI works in 2026: voice agents that call payer help lines and navigate IVR trees. Portal automation that logs into UnitedHealthcare, Aetna, Cigna, and Blue Cross subsidiaries and extracts the benefit summary. Language model extraction of benefit response documents into structured fields the rest of the workflow can consume.
Metric to watch: BV completion rate within 24 hours of intake.
Prior Authorization
Prior authorization is the most consequential workflow in the hub. The AMA's 2024 nationwide survey of 1,000 practicing physicians found that 78% report PA leads to patient treatment abandonment, 94% report PA delays patient access to care, and 19% report PA-driven serious adverse events that led to hospitalization (AMA 2024 Prior Authorization Survey). On average, a physician's practice completes 43 PAs per physician per week and spends 12 hours of staff time per week on the workflow.
Where it breaks: payer-specific clinical criteria, missing chart pulls, peer-to-peer requirements, appeals loops that restart the clock.
Where AI works in 2026: medical policy matching against the patient chart, pre-filled questionnaires extracted from clinical documentation, electronic PA submission through CoverMyMeds and similar networks, appeal letter drafting against denial reasons.
A compliance note worth flagging. CMS-0057-F's 72-hour and 7-day PA decision timeframes and FHIR API requirements explicitly exclude drug prior authorizations. The rule applies to medical items and services. Drug PA remains governed by state PA reform laws (which vary widely) and payer contracts. Any hub operating across multiple drugs and multiple states must build state-by-state PA compliance.
Metric to watch: PA submission turnaround and approval rate by payer.
Copay and Financial Assistance Enrollment
A specialty drug at a $500 monthly copay produces a different abandonment curve than the same drug at a $50 copay. Specialty drug abandonment rates climb from 1.3-10% at low cost sharing to 32-75% when patient cost sharing exceeds $100 (peer-reviewed analysis cited across specialty pharmacy literature). The hub's job is to find a copay card, foundation grant, or patient assistance program that takes the out-of-pocket cost out of the abandonment zone.
Where it breaks: foundation funding windows open and close; eligibility documentation expires; anti-kickback safeguards constrain how routing decisions get made; independent 501(c)(3) foundations require strict separation from manufacturer influence.
Where AI works in 2026: foundation match against diagnosis, household income, and insurance type. Document collection workflows that text or email the patient for proof of income. Recertification reminders before grants expire. Audit logging that demonstrates AKS-compliant routing.
Metric to watch: percentage of cases with cost sharing reduced to under $50 within seven days of BV.
Fulfillment and Specialty Pharmacy Routing
Once coverage and affordability are resolved, the hub routes the patient to a specialty pharmacy or infusion site. Payer-mandated limited distribution networks complicate this: the patient's preferred pharmacy may not be the one the payer requires.
Where it breaks: limited distribution network mismatches, cold chain coordination for biologics, site-of-care decisions when both home infusion and infusion center are viable.
Where AI works in 2026: routing logic that resolves network constraints against patient geography. Shipment status tracking. Refill orchestration that anticipates the next ship date and starts the workflow early enough to prevent gaps.
Metric to watch: first-fill ship date vs. PA approval date.
REMS and Regulatory Attestation
The FDA maintains active Risk Evaluation and Mitigation Strategies (REMS) programs for medications where serious safety risks require additional controls beyond standard labeling (FDA REMS). REMS applies to drugs, not medical services. The compliance burden falls on hubs, specialty pharmacies, and prescribers who must verify enrollment, complete training, and document patient-level attestations.
Where it breaks: prescriber enrollment lapses, pharmacy certification gaps, missed lab attestations, patient counseling documentation that fails audit.
Where AI works in 2026: workflow gating that blocks dispense events without a current REMS attestation. Reminder workflows for prescriber re-enrollment. Audit log capture for every REMS-relevant action.
Metric to watch: zero REMS-related ship blocks at audit, zero dispense events without attestation.
Adherence and Care Coordination
Once the patient is on therapy, the hub's job is keeping them on therapy. Refill timing, missed-dose intervention, side effect triage, lab and follow-up coordination.
Where it breaks: patient phone numbers go stale; refills lapse without notice; side effects cause patients to stop without telling anyone.
Where AI works in 2026: outbound check-in calls with structured questions and natural conversational handling. Persistence prediction models that flag at-risk patients to a human nurse case manager. Side effect triage that follows clinical protocols and escalates when patient-reported symptoms cross a defined threshold.
Metric to watch: persistence at 90 and 180 days.
Missing Information Resolution and Exception Loops
The eighth workflow is the one most hub leaders underestimate. The majority of cases at any given moment are not progressing because something is missing from the prescriber, the payer, or the patient. Phone numbers that need a callback. Lab values not yet returned. PA denial reasons that need an appeal.
Where AI works in 2026: outbound calls and faxes back to prescriber offices. Pattern recognition on which information is most often missing per payer, allowing the hub to ask for it upfront on the next case. Automated re-requests against a clock.
Metric to watch: number of cases in "awaiting information" state at the start and end of each day.
What an Orchestrated Hub Actually Looks Like
The eight workflows above can be run in three meaningfully different ways. The architecture choice determines whether the hub scales with launches or breaks under them.
Architecture | How it runs | Where it breaks |
|---|---|---|
Sequential manual | Call center, spreadsheets, fax queues, email handoffs | Errors compound across handoffs; no visibility across cases; cannot absorb launch volume |
Point-tool stack | ePA tool, eBV tool, CRM, separate adherence platform, each owning state | Each tool owns its own data; manual reconciliation; gaps between tools; no single view of the case |
AI workforce orchestration | One state machine, AI agents own discrete workflows, humans handle exceptions | Requires AI maturity; harder to procure; tied to vendor's roadmap if not consultative |
The orchestrated architecture, the one Neon Health builds for, treats the case as the unit of work. Every case has one of roughly 15 named states, every transition is logged, every action attaches to either an AI agent or a human owner. The decisioning layer is where rules, AI judgment, and human-in-the-loop intersect. Routine BV calls go to the voice agent. A case where the payer's portal has been redesigned overnight goes to a human, while the system learns the new portal flow for next time.
This is not theoretical. The CAQH 2025 Index documents that the U.S. healthcare system avoided $258 billion in administrative costs in 2024 through electronic transactions and improved data exchange, with a remaining $21 billion opportunity in administrative workflows that are still manual or only partially automated (CAQH 2025 Index). More than 50% of health plans and 25% of provider organizations now use AI tools in administrative workflows. Pharma hubs sit squarely in that automation opportunity.
The ROI math at the case level is directional, not precise. A small reduction in time-to-BV compresses time-to-therapy. Time-to-therapy correlates with abandonment risk. Reduced abandonment means more patients on therapy, more revenue at the manufacturer level, and lower cost-per-patient at the hub level. Pinning a precise dollar figure to a single case requires assumptions about drug price, payer mix, and abandonment curve that vary by program. What does not vary is the direction.
The 2026 Vendor Landscape
Three categories of vendor compete for orchestration spend in 2026. None of them owns the term "hub workflow orchestration" yet, which is part of why the term is worth defining clearly.
Full-service hub providers run end-to-end execution. ConnectiveRx, Lash Group, AssistRx, CareMetx, Eversana, and McKesson RxO each operate large patient access programs with their own technology platforms and human teams. Orchestration in these models is a workflow management feature inside a service offering, not the product itself. Industry consolidation has shaped what these stacks look like: Eversana acquired Dohmen Life Sciences Services, CareMetx acquired Biosolutia and Virmedica, ConnectiveRx acquired Macaluso Group. Each acquisition added a workflow capability that the parent then integrated. The result is broad coverage with depth that varies by acquired component.
AI-native automation layers treat orchestration as the core product. Mandolin raised $40 million in June 2025 and has deployed across more than 700 clinical locations, with AI agents that handle intake, benefit verification, out-of-pocket estimation, prior authorization, claims, and appeals (BusinessWire, June 2025). Infinitus partnered with IBM Consulting in 2025 to bring agentic AI into specialty pharmacy workflows targeted at PA cycle time and BV (MobiHealthNews). Neon Health composes voice agents, portal automation, and rules engines into bespoke orchestration for each customer, with HIPAA, HITRUST, and SOC 2 as the floor.
Point tools solve one slice deeply. CoverMyMeds for ePA. Surescripts for eBV and electronic prescription routing. Waystar for claims and revenue cycle. Salesforce Health Cloud for case management. None of these is an orchestrator by itself, but each plays a role inside one. A full-service hub or AI-native layer typically integrates several point tools and adds the orchestration layer on top.
The investment signal in this market is clear. The Grand View Research projection of $7.63 billion by 2033 includes AI integration as a primary growth driver. The report cites Wellgistics Health's August 2025 launch of HubRx AI, an AI platform automating eligibility checks, claims management, and reimbursement support, as one example of what AI orchestration looks like in practice (Grand View Research).
For a head-to-head comparison of patient hub platforms with named pricing tiers and feature breakdowns, see our patient hub platforms guide. The piece here is the workflow-orchestration layer that sits above any of those platforms.
Compliance and Regulatory Architecture
A modern hub crosses a wide compliance surface every day. The orchestration layer is what makes the surface auditable.
Regulation | Scope | Where it touches the workflow |
|---|---|---|
HIPAA / HITECH | PHI handling | Every system, every BAA, encryption in transit and at rest |
HITRUST CSF | Information security framework | Independent certification of HIPAA-aligned controls |
SOC 2 | Trust services criteria | Independent audit of security, availability, confidentiality |
TCPA | Outbound calls and texts | Express written consent required before outbound contact |
AKS (Anti-Kickback Statute) | Foundation routing, PAP design | No prescriber-induced steering, independent foundation governance |
FDA REMS | Drug-level FDA mandates | Workflow gating on attestation; applies to drugs, not services |
Sunshine Act | Manufacturer payments | Limited reporting requirements, usually routed through foundations |
State PA reform laws | Prior authorization timelines | Vary by state; drug PA is state-governed, not CMS-0057-F-governed |
A few subtleties worth naming.
REMS applies to drugs, not medical services. The FDA maintains a current list of approved REMS programs on its REMS page (FDA REMS); only a small subset of medications require one, but for those that do, orchestration must hard-block dispense events when REMS attestation is missing or expired. Soft-block patterns lead to audit findings.
CMS-0057-F's PA reform requirements, including the 72-hour decision timeframe and FHIR API mandates, explicitly exclude drug prior authorizations. The rule applies to medical items and services. The follow-on CMS-0062-P proposed rule, released by CMS in 2026, would extend several of the same interoperability and PA requirements to drug PA, but it is a proposed rule and has not been finalized at the time of writing (CMS-0062-P). Today, drug PA timelines remain governed by state PA reform laws and payer-specific contracts. Hubs operating across multiple drugs and multiple states should track the CMS-0062-P finalization while building state-by-state compliance.
The audit-trail requirement runs through everything. AI orchestration must produce a per-case, per-action audit log: every outbound call, every payer portal action, every clinical attestation, every state transition. Procurement teams at pharma manufacturers will not approve a vendor whose audit log cannot answer the question "what did the AI agent do at 11:43 on Tuesday for patient X?"
Frequently Asked Questions
What is the difference between a patient hub and hub workflow orchestration?
The patient hub is the program: the team, technology, and services running patient access for a specialty drug. Hub workflow orchestration is the layer that sequences the hub's discrete workflows (intake, BV, PA, copay, fulfillment, REMS, adherence) into one accountable pipeline with state tracking and decisioning logic. A hub can exist without orchestration; it just runs slower and with more handoffs.
How is AI changing hub services in 2026?
AI is replacing manual portal navigation, payer phone calls, and document extraction with AI agents that run the same workflows around the clock. The 2025 CAQH Index reports that more than 50% of health plans and 25% of providers now use AI tools in administrative workflows (CAQH 2025 Index). The shift specific to hub operations is from single-task automation to end-to-end orchestration.
Does hub workflow orchestration require integrations with payer systems?
Not always. A modern AI workforce can operate the same channels a human team uses: payer portals, IVR phone trees, and fax. Integration accelerates execution where APIs exist, but the absence of an API is no longer a blocker for orchestration. This matters because most payers do not expose APIs for specialty drug coverage details.
What does HIPAA and HITRUST compliance mean for an AI hub?
Every AI agent action must produce an audit log, all PHI must be encrypted in transit and at rest, and access must be role-gated. HITRUST and SOC 2 certifications attest that controls have been independently audited. Pharma manufacturers gate vendor decisions on these certifications. A hub orchestration platform without HIPAA, HITRUST, and SOC 2 will not survive procurement at most pharma buyers.
How is hub workflow orchestration different from a specialty pharmacy management platform?
A specialty pharmacy platform runs the pharmacy itself: dispense, fulfillment, refill management, clinical coordination. Hub orchestration runs the upstream and downstream workflows that determine whether a prescription ever reaches the pharmacy: intake, BV, PA, copay, adherence, and reauthorization. The two work together; neither replaces the other.
Do CMS-0057-F prior authorization rules apply to drug PAs?
No. CMS-0057-F's 72-hour and 7-day decision timeframes and FHIR API requirements explicitly exclude drug prior authorizations. The rule applies to medical items and services. The follow-on CMS-0062-P proposed rule released in 2026 would extend similar requirements to drugs, but it is not yet final. Until then, drug PA timelines remain governed by state PA reform laws and payer-specific contracts.
Key Takeaways
Hub workflow orchestration sequences eight discrete workflows (intake, BV, PA, copay, fulfillment, REMS, adherence, exception handling) into one accountable pipeline with state tracking and decisioning logic.
The global pharma hub and patient access support service market is projected to reach $7.63 billion by 2033, growing at 10% CAGR, with AI integration as a primary growth driver (Grand View Research).
Only 22% of prescribers say specialty therapy initiates within two weeks despite 82% believing it should, a gap that reflects unorchestrated workflow debt (Surescripts Specialty Medications Data Brief).
Seventy-eight percent of physicians report that prior authorization leads to patient treatment abandonment, and 94% report PA delays care (AMA 2024 Prior Authorization Survey).
The 2026 shift in hubs is from single-task automation to AI workforce orchestration, with $21 billion in remaining administrative automation opportunity across U.S. healthcare (CAQH 2025 Index).
REMS applies to drugs, not medical services, and CMS-0057-F PA reform timelines explicitly exclude drug PAs. The 2026 CMS-0062-P proposed rule would extend PA requirements to drugs but is not final. Drug-level compliance requires separate workflow architecture (FDA REMS, CMS-0062-P).
HIPAA, HITRUST, and SOC 2 are the procurement floor for any hub orchestration vendor. A complete, per-case audit log is the operational floor.
Closing
The hub of 2026 is not a call center with technology bolted on. It is an orchestrated AI workforce composed of voice agents, portal automation, and decisioning, with humans handling exceptions. The vendors who win this decade will be the ones who treat orchestration as the product, not as a feature inside a service offering.
At Neon Health, we build that workforce. Modular voice, portal, and rules-engine components composed for each customer's workflows. HIPAA, HITRUST, and SOC 2 as the floor. Consultative implementation because no two hubs look the same.
For a head-to-head comparison of patient hub platforms, see patient hub platforms compared. For the workflow-level view of how AI agents fit into healthcare operations more broadly, see AI agents in healthcare. To see how Neon orchestrates these workflows for your program, schedule a consultation.
Sources
Primary Sources
AMA. "Exhausted by prior auth, many patients abandon care: AMA survey." 2024. https://www.ama-assn.org/practice-management/prior-authorization/exhausted-prior-auth-many-patients-abandon-care-ama-survey
CAQH. "2025 CAQH Index: $258 billion avoided through automation, interoperability, and AI adoption." 2025. https://www.caqh.org/blog/2025-caqh-index-shows-u.s.-healthcare-avoided-258-billion-and-accelerated-automation-interoperability-and-ai-adoption
CMS. "2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P)." 2026. https://www.cms.gov/priorities/burden-reduction/overview/interoperability/policies-regulations/cms-interoperability-standards-prior-authorization-drugs-proposed-rule-cms-0062-p
FDA. "Risk Evaluation and Mitigation Strategies (REMS)." Accessed May 2026. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
Grand View Research. "Pharma Hub And Patient Access Support Service Market Report, 2024-2033." 2025. https://www.grandviewresearch.com/industry-analysis/pharma-hub-patient-access-support-service-market-report
Surescripts. "Specialty Medications Data Brief." 2022. https://surescripts.com/lp/specialty-medications-data-brief-2022
Secondary Sources
BusinessWire. "Mandolin Raises $40M to Improve Access to Life-Saving Therapies for Diseases like Cancer and Alzheimer's Using AI Agents." June 2025. https://www.businesswire.com/news/home/20250625104094/en/Mandolin-Raises-$40M-to-Improve-Access-to-Life-Saving-Therapies-for-Diseases-like-Cancer-and-Alzheimers-Using-AI-Agents
MobiHealthNews. "Infinitus, IBM Consulting team up for agentic AI." 2025. https://www.mobihealthnews.com/news/infinitus-ibm-consulting-team-agentic-ai
Pharmacy Times. "Accelerate Time to Specialty Pharmacy Therapy with Digital Options." https://www.pharmacytimes.com/view/accelerate-time-to-specialty-pharmacy-therapy-with-digital-options
AJMC. "2024 CAQH Index Foresees Major Opportunity for Health Care Savings." 2024. https://www.ajmc.com/view/2024-caqh-index-foresees-major-opportunity-for-health-care-savings
ConnectiveRx, Mandolin. Self-reported data from company websites. Accessed May 2026.
Related articles
Related articles
Ready to transform Patient Access?
Ready to transform Patient Access?
NEWSLETTER
@ 2026 Neon Health (Belay, Inc).
AI-powered patient access automation
for leading pharma enterprises.
NEWSLETTER
@ 2026 Neon Health (Belay, Inc).
AI-powered patient access automation for leading pharma enterprises.
NEWSLETTER
@ 2026 Neon Health (Belay, Inc).
AI-powered patient access automation
for leading pharma enterprises.